



261 Mountain View Dr  
 Colchester, VT 05446  
 License #: TLAB0030  
 802-767-7256  
 info@onwardanalytics.biz

# Certificate of Analysis

**Client Name:** Birdseye Botanicals  
**License Number:** CLTV0103

**Sample ID:** 20251103-26052  
**Sample Name:** Pumpernickle  
**Sample Lot:** CLTV0103-4-2  
**Sample Matrix:** Flower  
**Date Received:** 11/3/2025  
**Date Reported:** 11/7/2025  
**Date Tested:** 11/4/2025



**Total Terpenes (%) : 1.1784**

Dominant Terpenes (%)	
beta-caryophyllene	0.3427
Limonene	0.3146
alpha-Humulene	0.1608
Myrcene	0.1005
alpha-Bisabolol	0.0892

## Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #85496

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.0892	0.892	0.000003	0.001
alpha-Humulene	0.1608	1.608	0.000002	0.001
alpha-Pinene	0.0309	0.309	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	0.0076	0.076	0.000004	0.001
beta-caryophyllene	0.3427	3.427	0.000004	0.001
beta-Pinene	0.0582	0.582	0.000002	0.001
Camphene	0.0042	0.042	0.000001	0.001
Caryophyllene Oxide	0.0289	0.289	0.000011	0.001
Eucalyptol	ND	ND	0.000002	0.001
gamma-Terpinene	ND	ND	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	ND	ND	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.3146	3.146	0.000002	0.001
Linalool	0.0408	0.408	0.000003	0.001
Nerolidol	ND	ND	0.000007	0.001
Myrcene	0.1005	1.005	0.000003	0.001
Ocimene	ND	ND	0.000002	0.001
<b>Total Terpenes</b>	<b>1.1784</b>	<b>11.784</b>		

*Callie Chapman*

Callie Chapman  
 Lab Director  
 11/7/2025

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

